Slowing the progression of renal failure

Kidney International, Supplement

Volumn 61, Issue 80, 2002, Pages

  Praga, Manuel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; Hyperlipidemia; Obesity; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN;

ANEMIA; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXERCISE; FOCAL GLOMERULONEPHRITIS; GENETICS; GLOMERULONEPHRITIS; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MALNUTRITION; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROSCLEROSIS; OBESITY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; REFLUX NEPHROPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SMOKING CESSATION; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS; REVIEW; SOCIOECONOMICS; TIME;

DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 0035999918     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.61.s80.5.x     Document Type: Conference Paper

References (33)

1. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
2. Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes
3. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
4. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes
5. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
6. Randomised placebo-controlled trial of effect of ramipril on declining in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
7. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials
8. Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria
9. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
10. Angiotensin converting enzyme gene polymorphisms and ACE inhibition in diabetic nephropathy
11. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies
12. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity
13. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis
14. Obesity-related glomerulopathy: An emerging epidemic
15. Should all patients with diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors?
16. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
17. Add-on angiotensin receptor blockade with maximized ACE inhibition
18. Dietary protein restriction and the progression of chronic renal disease: What have all the results of the MDRD study shown?
19. A meta-analysis of the effects of dietary protein restrictions on the rate of decline in renal function
20. Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake
21. How long can dialysis be postponed by low protein diet and ACE inhibitors?
22. Effect of lipid reduction on the progression of renal disease: A meta-analysis
23. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy
24. Effects of maternal protein restriction on the kidneys of the newborn young of rats
25. Intrauterine growth retardation and development of endocrine pancreas in the experimental rat
26. Relationship between weight at birth and the number and size of renal glomeruli in humans: A histomorphometric study
27. The fetal and childhood growth of persons who develop type 2 diabetes
28. Diabetic end-stage renal disease among Native Americans
29. Smoking as a risk factor for end-stage renal failure in men with primary renal disease
30. Effects of recombinant human erythropoietin on renal function in chronic renal failure in predialysis patients
31. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
32. Progressive renal disease: The chronic hypoxia hypothesis
33. Renoprotection: One or many therapies?